Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 272

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Fayers, Peter M., Palumbo, Antonio, Hulin, Cyrille, Waage, Anders, Wijermans, Pierre, Beksaç, Meral, Bringhen, Sara, Mary, Jean-Yves, Gimsing, Peter, Termorshuizen, Fabian, Haznedar, Rauf, Caravita, Tommaso, Moreau, Philippe, Turesson, Ingemar, Musto, Pellegrino, Benboubker, Lotfi, Schaafsma, Martijn, Sonneveld, Pieter, Facon, Thierry, on behalf of the Nordic Myeloma Study Group, Italian Multiple Myeloma Network, Turkish Myeloma Study Group, Hemato-Oncologie voor Volwassenen Nederland, Intergroupe Francophone du Myélome, and European Myeloma Network·2011·Blood
DOI 10.1182/blood-2011-03-341669
Open this paper in CoChat — free account

Abstract

The role of thalidomide for previously untreated elderly patients with multiple myeloma remains unclear. Six randomized controlled trials, launched in or after 2000, compared melphalan and prednisone alone (MP) and with thalidomide (MPT). The effect on overall survival (OS) varied across trials. We carried out a meta-analysis of the 1685 individual patients in these trials. The primary endpoint was OS, and progression-free survival (PFS) and 1-year response rates were secondary endpoints. There was a highly significant benefit to OS from adding thalidomide to MP (hazard ratio = 0.83; 95% confidence interval 0.73-0.94, P = .004), representing increased median OS time of 6.6 months, from 32.7 months (MP) to 39.3 months (MPT). The thalidomide regimen was also associated with superior PFS (hazard ratio = 0.68, 95% confidence interval 0.61-0.76, P < .0001) and better 1-year response rates (partial response or better was 59% on MPT and 37% on MP). Although the trials differed in terms of patient baseline characteristics and thalidomide regimens, there was no evidence that treatment affected OS differently according to levels of the prognostic factors. We conclude that thalidomide added to MP improves OS and PFS in previously untreated elderly patients with multiple myeloma, extending the median survival time by on average 20%.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-03-341669

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 272

Metadata

Authors
Fayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J.-Y., Gimsing, P., Termorshuizen, F., Haznedar, R., Caravita, T., Moreau, P., Turesson, I., Musto, P., Benboubker, L., Schaafsma, M., Sonneveld, P., Facon, T., & on behalf of the Nordic Myeloma Study Group, I. M. M. N.
Venue
Blood
Publisher
American Society of Hematology
Published
2011-08-04
Volume
118
Issue
5
Pages
1239-1247
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2011-03-341669
OpenAlex
W2078752778
Cited by
272
References
25
FWCI
4.51
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. https://app.cochat.ai/papers/10.1182/blood-2011-03-341669
The paper
Fayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J.-Y., Gimsing, P., Termorshuizen, F., Haznedar, R., Caravita, T., Moreau, P., Turesson, I., Musto, P., Benboubker, L., Schaafsma, M., Sonneveld, P., Facon, T., & on behalf of the Nordic Myeloma Study Group, I. M. M. N. (2011). Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. https://doi.org/10.1182/blood-2011-03-341669

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.